https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00010-5/fulltext
0
0
2/3/23 at 11:34pm
Organization
The Lancet
Authors
SARS-CoV-2 subvariants BQ.1.1 and XBB.1 have been circulating globally with superior
growth advantages over most omicron mutants (appendix p 5). However, XBB.1.5, a subvariant
of the recombinant mutant XBB, has shown a substantial growth advantage compared wi…
Create an account
or login to join the discussion